Public Employees Retirement System of Ohio Sells 1,150 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Public Employees Retirement System of Ohio cut its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,381 shares of the biotechnology company’s stock after selling 1,150 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in United Therapeutics were worth $6,228,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in UTHR. MML Investors Services LLC bought a new stake in United Therapeutics in the third quarter worth about $245,000. Dorsey Wright & Associates purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $2,067,000. Main Management ETF Advisors LLC purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $834,000. Orion Portfolio Solutions LLC raised its holdings in shares of United Therapeutics by 60.1% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 3,286 shares of the biotechnology company’s stock worth $1,178,000 after purchasing an additional 1,233 shares during the period. Finally, World Investment Advisors LLC purchased a new position in United Therapeutics in the third quarter valued at approximately $139,206,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Argus raised their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company boosted their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 7,796 shares of United Therapeutics stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84. Following the sale, the chief financial officer now directly owns 4,264 shares of the company’s stock, valued at approximately $1,509,626.56. This trade represents a 64.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 119,340 shares of company stock valued at $44,765,530 over the last three months. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

United Therapeutics stock opened at $361.81 on Friday. The stock has a market cap of $16.15 billion, a P/E ratio of 15.89, a PEG ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The firm’s fifty day moving average price is $369.94 and its 200-day moving average price is $341.68.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.38 EPS. Sell-side analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.